Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib

Annals of Oncology

Volumn 23, Issue 8, 2012, Pages 2103-2108

  Dranitsaris, G ^a   Vincent, M D ^b   Yu, J ^c   Huang, L ^c   Fang, F ^c   Lacouture, M E ^d  

^a Caduceus Information Systems Inc   (Canada)

^b LONDON REGIONAL CANCER PROGRAM   (Canada)

^c Global Biologics Research   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Hand foot skin reaction; Prediction; Renal cell carcinoma; Risk; Sorafenib

Indexed keywords

PLACEBO; SORAFENIB;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; GENDER; HAND FOOT SYNDROME; HUMAN; KIDNEY CARCINOMA; LEUKOCYTE COUNT; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; TREATMENT DURATION;

EID: 84864947860     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr580     Document Type: Article

References (25)

1. McKeage K, Wagstaff AJ Sorafenib: in advanced renal cancer. Drugs 2007; 67: 475-483.
2. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134.
3. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
4. Abou-Alfa GK, Johnson P, Knox JJ et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 2010; 304: 2154-2160.
5. Hutson TE, Bellmunt J, Porta C Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET. Eur J Cancer 2010; 46: 2432-2440.
6. Kim DH, Son IP, Lee JW et al. Sorafenib -induced hand-foot skin reaction with facial erythema. Ann Dermatol 2011; 23: 119-122.
7. Cuesta L, Betlloch I, Toledo F et al. Severe sorafenib-induced hand-foot skin reaction. Dermatol Online J 2011; 17: 14.
8. Zhang L, Zhou Q, Ma L et al. Meta-analysis of dermatological toxicities associated with sorafenib. Clin Exp Dermatol 2011; 36: 344-350.
9. Autier J, Escudier B, Wechsler J et al. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol 2008; 144: 886-892.
10. Abushullaih S, Saad ED, Munsell M, Hoff PM Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a singleinstitution experience. Cancer Invest 2002; 20: 3-10.
11. Meta-Analysis Group in Cancer Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 1998; 16: 3537-3541.
12. Lyman GH, Lyman CH, Agboola O Risk models for predicting chemotherapyinduced neutropenia. Oncologist 2005; 10: 427-437.
13. Dranitsaris G, Joy A, Young S et al. Identifying patients at high risk for nausea and vomiting after chemotherapy: the development of a practical prediction tool. J Support Oncol 2009; 7: W1-W8.
14. Dranitsaris G, Rayson D, Vincent M et al. Identifying patients at high risk for neutropenic complications during chemotherapy for metastatic breast cancer with doxorubicin or pegylated liposomal doxorubicin: the development of a prediction model. Am J Clin Oncol 2008; 31: 369-374.
15. La Vine DB, Coleman TA, Davis CH et al. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma. Am J Clin Oncol 2010; 33: 217-220.
16. George SL Identification and assessment of prognostic factors. Semin Oncol 1988; 15: 462-471.
17. Allison PD Logistic Regression Using the SAS System: Theory and Application, Chapter 8 Cary, NC: SAS Institute Inc. 1999; 179-216.
18. Rabe-Hesketh S, Everitt B Statistical Analysis Using Stata, Chapter 9 New York: Chapman & Hall 2000; 119-136.
19. Lyman GH, Kuderer NM A primer in prognostic and predictive models: development and validation of neutropenia risk models. Support Cancer Ther 2005; 2: 168-175.
20. Steyerberg EW, Eijkemans MJ, Harrell FE, Jr. et al. Prognostic modeling with logistic regression analysis: in search of sensible strategies in small data sets. Med Decis Making 2001; 21: 45-56.
21. Steyerberg EW, Harrell FE, Jr., Borsboom GJ et al. Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol 2001; 54: 774-781.
22. Beck J, Procopio G, Bajetta E et al. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. Ann Oncol 2011; 22: 1812-1823.
23. Hanley JA, McNeil BJ The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143: 29-36.
24. McNeil BJ, Hanley JA Statistical approaches to the analysis of receiver operating characteristic (ROC) curves. Med Decis Making 1984; 4: 137-150.
25. Azad NS, Aragon-Ching JB, Dahut WL et al. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination antivascular endothelial growth factor therapy. Clin Cancer Res 2009; 15: 1411-1416.